SG Americas Securities LLC trimmed its position in shares of Replimune Group, Inc. (NASDAQ:REPL – Get Rating) by 42.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,618 shares of the company's stock after selling 13,481 shares during the quarter. SG Americas Securities LLC's holdings in Replimune Group were worth $322,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the company. Harbor Capital Advisors Inc. boosted its holdings in shares of Replimune Group by 1.7% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 30,695 shares of the company's stock worth $537,000 after buying an additional 513 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of Replimune Group by 6.7% in the 2nd quarter. Legal & General Group Plc now owns 8,324 shares of the company's stock worth $146,000 after buying an additional 526 shares during the last quarter. Virtus ETF Advisers LLC boosted its holdings in shares of Replimune Group by 25.9% in the 2nd quarter. Virtus ETF Advisers LLC now owns 7,108 shares of the company's stock worth $124,000 after buying an additional 1,461 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Replimune Group by 5.2% in the 1st quarter. Rhumbline Advisers now owns 32,643 shares of the company's stock worth $554,000 after buying an additional 1,616 shares during the last quarter. Finally, Swiss National Bank boosted its holdings in shares of Replimune Group by 8.2% in the 1st quarter. Swiss National Bank now owns 49,900 shares of the company's stock worth $847,000 after buying an additional 3,800 shares during the last quarter. 87.83% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Pamela Esposito sold 15,000 shares of the company's stock in a transaction dated Friday, December 9th. The stock was sold at an average price of $25.03, for a total transaction of $375,450.00. Following the sale, the insider now directly owns 229,402 shares in the company, valued at $5,741,932.06. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 23.80% of the company's stock.

Replimune Group Trading Down 0.9 %

Replimune Group (NASDAQ:REPL – Get Rating) last announced its quarterly earnings results on Thursday, November 3rd. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.01). On average, equities analysts forecast that Replimune Group, Inc. will post -2.99 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on REPL. SVB Leerink boosted their price target on shares of Replimune Group from $30.00 to $34.00 and gave the stock an "outperform" rating in a report on Wednesday, December 7th. HC Wainwright lowered their price objective on Replimune Group from $60.00 to $48.00 and set a "buy" rating on the stock in a research note on Friday, November 4th. Piper Sandler boosted their price objective on Replimune Group from $43.00 to $58.00 in a research note on Wednesday, December 14th. EF Hutton Acquisition Co. I began coverage on Replimune Group in a research note on Thursday, January 5th. They issued a "buy" rating and a $60.00 price objective on the stock. Finally, BMO Capital Markets boosted their price objective on Replimune Group from $40.00 to $70.00 and gave the company an "outperform" rating in a research note on Monday, December 12th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $51.57.

About Replimune Group

(Get Rating)

Replimune Group, Inc, a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma.

Featured Stories

• Get a free copy of the StockNews.com research report on Replimune Group (REPL)
• Is Seagate Technology Signaling the End of its Normalization?
• eHealth Stock Rises from the Ashes. Time to Get In?
• Can Yext A.I. Search Platform Drive Growth in 2023?
• Cassava Sciences Stock Undervalued with Its $124 Price Target?
• Constellation Brands: Are Consumers Trading Down for Rail Drinks?

Want to see what other hedge funds are holding REPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Replimune Group, Inc. (NASDAQ:REPL – Get Rating).

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.